<DOC>
	<DOCNO>NCT01245725</DOCNO>
	<brief_summary>The purpose study determine whether efficacy tirofiban ( 25mcg/kg i.v . bolus follow 0.15mcg/kg/min i.v . infusion percutaneous coronary intervention ( PCI ) plus two hour procedure ) effective placebo set standard therapy ( e.g . aspirin , thienopyridine , unfractionated heparin bivalirudin ) among patient undergo PCI , assess incidence adverse cardiac ischemic event define death , myocardial infarction ( MI ) , urgent target vessel revascularization ( uTVR ) within 48 hour follow study drug initiation . A secondary objective study ass whether tirofiban ( 25mcg/kg i.v . bolus follow 0.15mcg/kg/min i.v . infusion PCI plus two hour procedure ) safe compare placebo set standard therapy ( e.g . aspirin , thienopyridine , unfractionated heparin bivalirudin ) among patient undergo PCI , assess incidence non-CABG-related TIMI major bleed within 48 hour follow study drug initiation . Patient enrollment pending .</brief_summary>
	<brief_title>Aggrastat Truncated Length Against Standard Therapies Percutaneous Coronary Intervention</brief_title>
	<detailed_description />
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Angina , Unstable</mesh_term>
	<mesh_term>Tirofiban</mesh_term>
	<criteria>1 . Age &gt; 18 year age 2 . Scheduled undergo PCI approve device 3 . Written inform consent 1 . Primary PCI STelevation myocardial infarction ( STEMI ) 2 . Prior PCI within 30 day 3 . Prior GPIIb/IIIa use within 14 day 4 . Prior enoxaparin use within 4 day 5 . Prior STEMI within 30 day 6 . In nonelective subject , rise troponin define recent prePCI sample great sample immediately precede , long two sample separate four hour analyze hospital laboratory .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>